Led by Academician Zhang Xu, a Member of the Chinese Academy of Sciences and an authority in the field of urology, the project saw the joint attendance of his top-tier research team and Xindou Biotechnology’s clinical team. As China’s first targeted fluorescent contrast agent approved for clinical use and compatible with surgical robots, this trial fills a gap in the global market—prior to this, no prostate cancer-targeted fluorescent contrast agent deeply compatible with surgical robots had been launched worldwide. This marks not only a milestone leap in the field of precision diagnosis and treatment of prostate cancer but also China’s leadership in the global race for innovation in tumor visualization technology.

Prostate cancer is the most common epithelial malignant tumor in the male genitourinary system. Traditional fluorescent contrast agents, due to insufficient targeting and specificity, lead to a high rate of positive surgical margins in prostate cancer. As China’s first near-infrared tumor-targeted fluorescent contrast agent approved for clinical use, Injection DGPR1008 enables "real-time visualization of tumor cells" during surgery via intravenous injection before the operation. With its high sensitivity, strong specificity, and excellent Tumor-to-Background Ratio (TBR), it accurately delineates tumor boundaries, identifies small lesions and metastatic lymph nodes, and significantly reduces normal tissue damage and postoperative recurrence risk. It provides surgeons with "visual surgical navigation," propelling prostate cancer surgery into a new era of "precision resection and ultimate safety."

Founded in 2021, SIGNDO Biotechnology is a pioneering enterprise in the global field of tumor-targeted fluorescent contrast agents. Guided by its mission "Light Up Tumors for Precision Surgery," the company has built a multi-cancer product portfolio using small-molecule fluorescent conjugation technology, relying on its globally leading RT-TFC® technology platform. It is committed to providing surgeons with comprehensive tumor visualization solutions for all scenarios. The in-depth collaboration with the Da Vinci Surgical System this time is not only the deep integration of technological innovation but also a model example of the coordinated breakthroughs of Intelligent Manufacturing in China in the fields of high-end medical equipment and novel contrast agents—bringing a more precise and safer surgical future to cancer patients worldwide.

The conference featured in-depth briefing and promotion on the research background, key technical aspects of the protocol, and implementation standards, marking China’s entry into a new phase of "robot compatibility + precision visualization" in the clinical development of tumor-targeted fluorescent contrast agents. In the future, with the accumulation of clinical data and technological iteration, Injection DGPR1008 is expected to reshape global standards for prostate cancer surgery and establish a Chinese benchmark in precision tumor diagnosis and treatment.

The Light of Technology Illuminates the Hope of Life — Xindou Biotechnology, Redefining Precision Surgery through Innovation!